MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) – Investment analysts at B. Riley issued their Q2 2023 earnings per share (EPS) estimates for shares of MiNK Therapeutics in a note issued to investors on Monday, November 14th. B. Riley analyst K. Patel expects that the company will post earnings of ($0.22) per share for the quarter. The consensus estimate for MiNK Therapeutics' current full-year earnings is ($0.84) per share.
Get
MiNK Therapeutics alerts:
MiNK Therapeutics (NASDAQ:INKT – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.04.
Separately, HC Wainwright initiated coverage on MiNK Therapeutics in a research note on Wednesday, August 10th. They set a "buy" rating and a $7.00 price objective for the company.
MiNK Therapeutics Stock Performance
MiNK Therapeutics stock opened at $3.07 on Tuesday. MiNK Therapeutics has a fifty-two week low of $1.09 and a fifty-two week high of $21.40. The company has a market capitalization of $103.67 million and a P/E ratio of -3.93. The stock has a 50-day simple moving average of $2.26 and a 200-day simple moving average of $1.91.
Hedge Funds Weigh In On MiNK Therapeutics
An institutional investor recently bought a new position in MiNK Therapeutics stock. First Republic Investment Management Inc. purchased a new position in MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 81,500 shares of the company's stock, valued at approximately $172,000. First Republic Investment Management Inc. owned 0.24% of MiNK Therapeutics at the end of the most recent reporting period. 1.07% of the stock is currently owned by institutional investors.
MiNK Therapeutics Company Profile
(Get Rating)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
Read More
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- Power Integrations Stock Can Power Your Portfolio
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Three Penny Stocks Making Big Moves In November
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
